Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) had its price target dropped by equities researchers at JPMorgan Chase & Co. from $82.00 to $80.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has an "overweight" rating on the biopharmaceutical company's stock. JPMorgan Chase & Co.'s price target points to a potential upside of 106.00% from the company's previous close.
Other research analysts have also issued reports about the company. Needham & Company LLC decreased their price objective on Xenon Pharmaceuticals from $78.00 to $60.00 and set a "buy" rating on the stock in a report on Friday, September 18th. Wall Street Zen cut Xenon Pharmaceuticals from a "sell" rating to a "strong sell" rating in a report on Sunday, October 11th. Wedbush reduced their target price on Xenon Pharmaceuticals from $71.00 to $55.00 and set an "outperform" rating on the stock in a report on Friday, September 18th. Wells Fargo & Company decreased their price target on Xenon Pharmaceuticals from $69.00 to $64.00 and set an "overweight" rating on the stock in a research report on Friday, September 18th. Finally, Deutsche Bank downgraded Xenon Pharmaceuticals from a "buy" rating to a "hold" rating and dropped their price target for the company from $90.00 to $46.00 in a research note on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $71.15.
View Our Latest Stock Analysis on XENE
Xenon Pharmaceuticals Stock Performance
NASDAQ:XENE traded down $0.42 on Tuesday, reaching $38.84. The company's stock had a trading volume of 344,332 shares, compared to its average volume of 1,381,743. Xenon Pharmaceuticals has a 1-year low of $33.38 and a 1-year high of $72.66. The business's 50-day moving average price is $40.72 and its two-hundred day moving average price is $52.11. The firm has a market cap of $3.75 billion, a PE ratio of -8.25 and a beta of 0.11.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.13) by $0.02. As a group, sell-side analysts expect that Xenon Pharmaceuticals will post -4.62 EPS for the current year.
Insiders Place Their Bets
In other news, CEO Ian Mortimer bought 30,000 shares of the company's stock in a transaction on Wednesday, September 30th. The stock was purchased at an average cost of $37.38 per share, for a total transaction of $1,121,400.00. Following the completion of the transaction, the chief executive officer owned 49,923 shares of the company's stock, valued at $1,866,121.74. This trade represents a 150.58% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Christopher Kenney sold 7,068 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $60.25, for a total transaction of $425,847.00. Following the sale, the insider owned 2 shares in the company, valued at approximately $120.50. This represents a 99.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.91% of the company's stock.
Institutional Trading of Xenon Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its position in shares of Xenon Pharmaceuticals by 60.2% in the 3rd quarter. GAMMA Investing LLC now owns 830 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 312 shares during the period. Corient Private Wealth LP raised its stake in Xenon Pharmaceuticals by 1.5% during the second quarter. Corient Private Wealth LP now owns 28,732 shares of the biopharmaceutical company's stock worth $1,734,000 after buying an additional 430 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in Xenon Pharmaceuticals by 25.5% in the third quarter. Nisa Investment Advisors LLC now owns 2,297 shares of the biopharmaceutical company's stock valued at $85,000 after buying an additional 467 shares during the period. Arizona State Retirement System boosted its position in Xenon Pharmaceuticals by 2.3% during the second quarter. Arizona State Retirement System now owns 22,382 shares of the biopharmaceutical company's stock valued at $1,351,000 after acquiring an additional 513 shares during the last quarter. Finally, Covestor Ltd grew its holdings in Xenon Pharmaceuticals by 418.5% during the 3rd quarter. Covestor Ltd now owns 674 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 544 shares during the period. 95.45% of the stock is currently owned by institutional investors.
Xenon Pharmaceuticals Company Profile
(
Get Free Report)
Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for neurological disorders. The company's research emphasizes ion channels, proteins that help regulate the electrical activity of nerve cells. Its lead program is azetukalner, formerly known as XEN1101, an oral Kv7 potassium-channel opener being developed for seizure disorders, including focal epilepsy. Xenon is also advancing other drug candidates aimed at neurological conditions. Founded in 1996, Xenon is headquartered in Burnaby, British Columbia, and conducts drug development activities in North America.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.